Personalized ganciclovir dosing for CMV in children with weak immune systems
Part of Infections clinical trials.
This study tests whether a personalized dose of the antiviral drug ganciclovir can better treat CMV infection in children with weakened immune systems. It aims to make the treatment more effective and safer for each child.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child's immune system is weakened (from a transplant, chemotherapy, other medicines, or a condition they were born with)
- Your child has a measurable CMV infection in their blood and the doctor says treatment is needed
- Your child does not have severe kidney problems (a very low filtration rate)
- Your child has been on the study drugs for less than 3 days (or not at all)
- You and your child are willing to attend all study visits and follow the plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests valganciclovir to see if it can reduce CMV virus in the blood for people with advanced HIV and a low CD4 count. It aims to prevent CMV from causing serious disease.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This early-phase study tests high-concentration ganciclovir eye drops to treat cytomegalovirus (CMV) retinitis, a serious eye infection. It may help people who are hard to treat with regular (systemic) antiviral medicine or who face higher risks with an injection directly into the eye.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This study tracks how well ganciclovir (an antiviral medicine) works in transplant recipients who develop a resistant CMV infection. Researchers will review medical records to understand treatment success and patient outcomes.
Hear when a new Cytomegalovirus Viraemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.